
Opinion|Videos|May 14, 2024
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
2
FDA Approves Etuvetidigene Autotemcel, First Gene Therapy for Wiskott-Aldrich Syndrome
3
How IV Robotics Are Transforming Sterile Compounding, Supply Chain Control, and Workforce Efficiency
4
A Supplemental Blood Test to Bridge Gaps in Breast Cancer Screening Access
5






















































































































































































































